Livforsakringsbolaget Skandia Omsesidigt trimmed its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 5.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,696 shares of the medical research company’s stock after selling 3,600 shares during the period. Amgen makes up 1.0% of Livforsakringsbolaget Skandia Omsesidigt’s portfolio, making the stock its 18th biggest holding. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Amgen were worth $10,207,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Jackson Grant Investment Advisers Inc. lifted its stake in shares of Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after buying an additional 5 shares during the period. Ballentine Partners LLC lifted its stake in shares of Amgen by 0.3% in the second quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock valued at $620,000 after buying an additional 9 shares during the period. Hudock Capital Group LLC lifted its stake in shares of Amgen by 0.5% in the second quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock valued at $330,000 after buying an additional 10 shares during the period. South Texas Money Management Ltd. lifted its stake in shares of Amgen by 0.7% in the second quarter. South Texas Money Management Ltd. now owns 3,223 shares of the medical research company’s stock valued at $555,000 after buying an additional 22 shares during the period. Finally, Burt Wealth Advisors raised its position in Amgen by 0.8% in the second quarter. Burt Wealth Advisors now owns 3,040 shares of the medical research company’s stock worth $523,000 after purchasing an additional 25 shares in the last quarter. Institutional investors own 78.03% of the company’s stock.
In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total transaction of $283,070.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 4,575 shares of company stock valued at $818,361. Company insiders own 0.19% of the company’s stock.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The business’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.89 EPS. equities research analysts forecast that Amgen, Inc. will post 13.21 EPS for the current year.
Amgen announced that its board has approved a stock buyback plan on Thursday, February 1st that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This is a positive change from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 annualized dividend and a dividend yield of 2.89%. Amgen’s dividend payout ratio (DPR) is presently 205.45%.
Several research firms recently issued reports on AMGN. Leerink Swann reissued a “market perform” rating on shares of Amgen in a research report on Friday, February 2nd. Atlantic Securities lowered shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price target for the company. in a research report on Monday, February 5th. Royal Bank of Canada dropped their price target on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a research report on Thursday, October 26th. Oppenheimer set a $205.00 price target on shares of Amgen and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, BidaskClub raised shares of Amgen from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. Sixteen research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Amgen has an average rating of “Hold” and a consensus price target of $191.84.
WARNING: This article was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2018/02/23/amgen-inc-amgn-holdings-cut-by-livforsakringsbolaget-skandia-omsesidigt.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.